Aptevo Therapeutics Earnings Date & Estimates

Aptevo Therapeutics (NASDAQ:APVO) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer and other serious diseases. The company’s research programs are designed to harness the immune system by directing immune cells toward specific disease-associated targets.

Aptevo’s pipeline is built primarily around its proprietary ADAPTIR bispecific antibody technology, which is intended to create therapeutic antibodies capable of binding to two different targets. Its investigational programs have included APVO436, an immune-cell engager targeting CD123 and CD3 for potential treatment of hematologic malignancies such as acute myeloid leukemia and myelodysplastic syndromes, as well as other preclinical and clinical immuno-oncology candidates.

The company was established as an independent business in 2016 through a separation from Emergent BioSolutions. Aptevo initially marketed IXINITY, a recombinant factor IX therapy for hemophilia B, before transitioning its strategic focus toward oncology and other targeted immunotherapies. Aptevo is headquartered in Seattle, Washington, and conducts its research and development activities through collaborations and clinical programs intended for patients in the United States and other international markets.